Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.26% | 16.50% | 10.97% | 4.78% | 7.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.26% | 16.50% | 10.97% | 4.78% | 7.90% |
| Cost of Revenue | -827.81% | 231.52% | -55.33% | -85.91% | 105.33% |
| Gross Profit | 30.36% | -48.13% | 19.08% | 39.40% | -24.63% |
| SG&A Expenses | 28.93% | -32.00% | 40.73% | 180.52% | 110.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.23% | 52.89% | -105.59% | 13.39% | 206.90% |
| Operating Income | 31.38% | -40.78% | 18.40% | -0.76% | -41.89% |
| Income Before Tax | -39.43% | -12.04% | 7.79% | 6.45% | -45.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.43% | -12.04% | 7.79% | 6.45% | -45.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 21.82% | -5.20% | 11.03% | -12.34% | 40.54% |
| Net Income | -49.10% | -44.42% | 23.12% | 2.88% | -47.75% |
| EBIT | 31.38% | -40.78% | 18.40% | -0.76% | -41.89% |
| EBITDA | 31.27% | -40.39% | -- | -- | -- |
| EPS Basic | -50.71% | -47.11% | 22.76% | 9.00% | -45.85% |
| Normalized Basic EPS | 134.01% | -175.39% | 66.76% | -65.88% | -55.54% |
| EPS Diluted | -50.80% | -46.31% | 23.23% | 9.00% | -45.78% |
| Normalized Diluted EPS | 142.79% | -179.90% | 73.68% | -65.88% | -54.57% |
| Average Basic Shares Outstanding | 3.28% | 5.09% | 0.30% | -5.60% | -3.52% |
| Average Diluted Shares Outstanding | -0.47% | -0.96% | -3.68% | -5.60% | -5.59% |
| Dividend Per Share | 6.82% | 6.82% | 6.82% | 4.76% | 4.76% |
| Payout Ratio | 1.17% | 1.02% | -0.11% | -0.02% | 0.94% |